These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

298 related items for PubMed ID: 18681317

  • 1. [Morphological features of basal-like subtype invasive carcinoma of breast].
    Gao LX, Yang GZ, Ding HY, Li L.
    Zhonghua Bing Li Xue Za Zhi; 2008 Feb; 37(2):83-7. PubMed ID: 18681317
    [Abstract] [Full Text] [Related]

  • 2. P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ.
    Paredes J, Lopes N, Milanezi F, Schmitt FC.
    Virchows Arch; 2007 Jan; 450(1):73-80. PubMed ID: 17123107
    [Abstract] [Full Text] [Related]

  • 3. Basal-like immunophenotype markers and prognosis in early breast cancer.
    Cassol L, Silveira Graudenz M, Zelmanowicz A, Cancela A, Werutsky G, Rovere RK, Garicochea B.
    Tumori; 2010 Jan; 96(6):966-70. PubMed ID: 21388060
    [Abstract] [Full Text] [Related]

  • 4. Identification of a basal-like subtype of breast ductal carcinoma in situ.
    Livasy CA, Perou CM, Karaca G, Cowan DW, Maia D, Jackson S, Tse CK, Nyante S, Millikan RC.
    Hum Pathol; 2007 Feb; 38(2):197-204. PubMed ID: 17234468
    [Abstract] [Full Text] [Related]

  • 5. [Clinicopathologic study of centrally necrotizing carcinoma of breast].
    Yu L, Yang WT, Cai X, Lu HF, Fan YZ, Shi DR.
    Zhonghua Bing Li Xue Za Zhi; 2009 Oct; 38(10):657-62. PubMed ID: 20078968
    [Abstract] [Full Text] [Related]

  • 6. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
    Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G.
    Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
    [Abstract] [Full Text] [Related]

  • 7. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.
    Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM.
    Mod Pathol; 2006 Feb; 19(2):264-71. PubMed ID: 16341146
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Roles of immunohistochemistry in prognostic assessment of basal-like breast cancer].
    Liu H, Fan QH, Zhang ZH, Li X, Yu HP, Liu GZ, Meng FQ.
    Zhonghua Bing Li Xue Za Zhi; 2009 Jan; 38(1):23-8. PubMed ID: 19489221
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Clinicopathologic features and immunohistochemistry of the basal-like subtype of invasive breast carcinoma].
    Liu LP, Bai J, Wei Y, Qi XD, Si TC, Li W, Pan H.
    Zhonghua Bing Li Xue Za Zhi; 2013 Feb; 42(2):101-5. PubMed ID: 23710916
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Protein expression profile and prevalence pattern of the molecular classes of breast cancer--a Saudi population based study.
    Al Tamimi DM, Shawarby MA, Ahmed A, Hassan AK, AlOdaini AA.
    BMC Cancer; 2010 May 21; 10():223. PubMed ID: 20492711
    [Abstract] [Full Text] [Related]

  • 15. Comparison of estrogen receptor, progesterone receptor and HER2 results in concurrent ipsilateral samples with invasive breast carcinoma: a retrospective study of 246 biopsies from 119 patients.
    Singh K, Wang Y, Marketkar S, Kalife ET, Steinhoff MM.
    Hum Pathol; 2017 Jul 21; 65():123-132. PubMed ID: 28457730
    [Abstract] [Full Text] [Related]

  • 16. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
    Khalifeh IM, Albarracin C, Diaz LK, Symmans FW, Edgerton ME, Hwang RF, Sneige N.
    Am J Surg Pathol; 2008 Apr 21; 32(4):544-52. PubMed ID: 18300793
    [Abstract] [Full Text] [Related]

  • 17. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer.
    Bryan BB, Schnitt SJ, Collins LC.
    Mod Pathol; 2006 May 21; 19(5):617-21. PubMed ID: 16528377
    [Abstract] [Full Text] [Related]

  • 18. Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2.
    Kusińska R, Potemski P, Jesionek-Kupnicka D, Kordek R.
    Pol J Pathol; 2005 May 21; 56(3):107-10. PubMed ID: 16334976
    [Abstract] [Full Text] [Related]

  • 19. Ductal invasive mammary carcinoma--clinicopathological prognostic factors related to immunohistochemical expression of hormonal receptors and Her2/neu oncoprotein.
    Recăreanu F, Simionescu C, Georgescu CV, Pirici E.
    Rom J Morphol Embryol; 2011 May 21; 52(3 Suppl):1059-64. PubMed ID: 22119825
    [Abstract] [Full Text] [Related]

  • 20. Comedo-DCIS is a precursor lesion for basal-like breast carcinoma: identification of a novel p63/Her2/neu expressing subgroup.
    Shekhar MP, Kato I, Nangia-Makker P, Tait L.
    Oncotarget; 2013 Feb 21; 4(2):231-41. PubMed ID: 23548208
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.